A symposium at EULAR 2016, held in London in June, addressed the targeting of unmet needs in autoantibody-driven inflammatory diseases, with a focus on seropositive rheumatoid arthritis (RA). The symposium, sponsored by Bristol-Myers Squibb, was chaired by Professor Paul Emery from the University of Leeds, UK. Professor Tom Huizinga, from the Department of Rheumatology at ...
Targeting treatment: Predictive and prognostic role of autoantibodies in RA
18 Oct 2016
Sponsored by Bristol-Myers Squibb Australia